Evidence map›Paper›PMID 41756243›Full record

ArticleFrontiers in pharmacology2026

Impaired adenosine pathways in HFpEF: insights into cardiorenal alterations and endothelial responses.

Maria Antonietta Riemma, Gennaro Madonna, Elena Mele, Elena Conte, Marialucia Telesca, Giacomo De Palma, Barbara Kutryb-Zając, Carla Cicala, Paola Imbrici, Antonella Liantonio and 7 more

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Maria Antonietta Riemma *Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
Gennaro Madonna *Department of Pharmacy, School of Medicine and Surgery, University of Naples "Federico II", Naples, Italy.
Elena MeleDepartment of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
Elena ConteDepartment of Pharmacy-Drug Sciences, University of Bari "Aldo Moro", Bari, Italy.
Marialucia TelescaDepartment of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
Giacomo De PalmaDepartment of Pharmacy, School of Medicine and Surgery, University of Naples "Federico II", Naples, Italy.
Barbara Kutryb-ZającDepartment of Biochemistry, Medical University of Gdansk, Gdańsk, Poland.
Carla CicalaDepartment of Pharmacy, School of Medicine and Surgery, University of Naples "Federico II", Naples, Italy.
Paola ImbriciDepartment of Pharmacy-Drug Sciences, University of Bari "Aldo Moro", Bari, Italy.
Antonella LiantonioDepartment of Pharmacy-Drug Sciences, University of Bari "Aldo Moro", Bari, Italy.
Antonella De AngelisDepartment of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
Konrad UrbanekDepartment of Molecular Medicine and Medical Biotechnologies, University of Naples "Federico II", CEINGE-Advanced Biotechnologies, Naples, Italy.
Liberato BerrinoDepartment of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
Armando IalentiDepartment of Pharmacy, School of Medicine and Surgery, University of Naples "Federico II", Naples, Italy.
Donato CappettaDepartment of Experimental Medicine, University of Salento, Lecce, Italy.
Maria DonniacuoDepartment of Experimental Medicine, University of Salento, Lecce, Italy.
Elisabetta CaiazzoDepartment of Pharmacy, School of Medicine and Surgery, University of Naples "Federico II", Naples, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart failure cases and lacks effective therapies. Key features of HFpEF include endothelial dysfunction, fibrosis, and oxidative stress. Adenosine signaling, regulated by enzymes and receptors, is critical for vascular homeostasis and inflammation, but its role in HFpEF remains poorly understood. Adenosine receptors are abundantly expressed in the heart and kidney, modulating vascular, fibrotic, and tubular processes. Dysregulation of adenosine pathways in either organ may drive hypertension, microvascular dysfunction, and maladaptive cardio-renal crosstalk, highlighting the need to investigate adenosine signaling as a combined multi-organ target. Methods: HFpEF was induced in Dahl salt-sensitive rats by high-salt diet. Cardiac structure, function, fibrosis, oxidative stress, cytokines, renal adenosine receptors and cardiac adenosine pathway components were assessed using echocardiography, histology, proteome profiling and Western blotting. Human cardiac microvascular endothelial cells were treated with endothelin-1 in the presence of selective A Results: Hypertensive rats exhibited diastolic dysfunction with preserved systolic function, cardiac and renal fibrosis, oxidative/nitrative stress, and elevated pro-inflammatory cytokines. Cardiac expression of CD39, CD73, and ADA enzymes was significantly reduced, indicating impaired adenosine metabolism, while transporters ENT2 and CNT2 were also downregulated, reflecting impairment of both equilibrative and concentrative adenosine transport. Adenosine receptor profiles were altered: A Conclusion: Impaired adenosine metabolism and transport, along with altered receptor signaling contribute to HFpEF progression. Selective A

Indexed as

adenosine deaminase inhibitionadenosine metabolismadenosine receptorsadenosine signalingcardiorenal crosstalkendothelial activationheart failure with preserved ejection fractionoxidative stress

Identifiers

PMID41756243
PMCPMC12932206

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.